Phasix™ Mesh: *40+ clinical publications and growing*

200K patients impacted

Changing the standard of care since 2013

LEGEND

- 2 for 2 year+ follow up
- 5 for 5 year+ follow up
- ✓ Data reported

QOL- Quality of Life

HEOR- Health, Economics, Outcomes, Research

NR – Not Reported

N/A – Not Applicable

Authors, Article Title, Journal, Year	Product	Patients	Mean Follow-up (Months)	Recurrence	Seroma	Surgical Site Infections	QOL	HEOR
Inguinal								
Abdullah Aldohayan, et. al. **A Novel Use of Fully Absorbable Phasix Mesh for Laparoscopic Inguinal Hernia Repair.** *JSLS* 2020	Phasix™ Mesh	15	30 2	0.0%	NR	NR		
Hiatal								
Benjamin Clapp, et. al. **Does bioabsorbable mesh reduce hiatal hernia recurrence rates? A meta-analysis.** *Surg Obes Relat Dis* 2022	Mesh vs. No Mesh	1351	Mesh: 28.8 No Mesh: 32.8 2	8.0%	NR	NR		
Aiolfi A, et. al. **Medium-term safety and efficacy profile of paraesophageal hernia repair with Phasix-ST mesh: a single-institution experience.** *Hernia* 2022	Phasix™ ST Mesh	68	27 2	8.8%	NR	NR	✓	
A Aiolfi, et. al. **Laparoscopic posterior cruroplasty: a patient tailored approach.** *Hernia* 2022	Phasix™ ST Mesh	**Phasix™ ST Mesh:** 39 **No Mesh**: 102	21	2.1%	NR	NR	✓	
Konstantinidis H, Charisis C. **Surgical treatment of large and complicated hiatal hernias with the new resorbable mesh with hydrogel barrier (Phasix ST): a preliminary study.** *J Robotic Surgery* 2022	Phasix ST™ Mesh	60	21	0.0%	NR	NR		
Konstantinidis H, Charisis C. **Surgical treatment of large and complicated hiatal hernias with the new resorbable mesh with hydrogel barrier (Phasix ST): a preliminary study.** *J Robotic Surgery* 2022	Phasix™ ST Mesh	60	21	0.0%	NR	NR		
Tommaso Panici Tonucci, et. al. **Safety and Efficacy of Crura Augmentation with Phasix ST Mesh for Large Hiatal Hernia: 3-Year Single-Center Experience.** *Laparoendosc Adv Surg Tech A* 2020	Phasix™ ST Mesh	73	17	3.2%	NR	0.0%	✓	
Walaa F Abdelmoaty, et. al. **Combination of Surgical Technique and Bioresorbable Mesh Reinforcement of the Crural Repair Leads to Low Early Hernia Recurrence Rates with Laparoscopic Paraesophageal Hernia Repair.** *J Gastrointest Surg* 2020	Phasix™ ST Mesh	50	12	8.0%	NR	0.0%		
Ventral								
Joseph F. Buell, et al. **Long-Term Outcomes in Complex Abdominal Wall Reconstruction Repaired With Absorbable Biologic Polymer Scaffold (Poly-4-Hydroxybutyrate).** *Ann Surg* (open) 2021	Phasix™ Mesh Strattice™	**Phasix™ Mesh:** 31 **Strattice™:** 42	60 5	**Phasix™ Mesh:** 12.9% **Strattice™:** 38.1% (p = 0.017)	NR	**Phasix™ Mesh:** 12.9% **Strattice™:** 31.0% (p = 0.071)		✓
Ankoor A. Talwar, et al. **Shifting the Goalpost in Ventral Hernia Care: 5-year Outcomes after Ventral Hernia Repair with Poly-4-hydroxybutyrate Mesh.** *Hernia* 2022	Phasix™ Mesh	43	60 5	20.0%	5.9%	3.9%	✓	
John Scott Roth, et al. **Long-Term, Prospective, Multicenter Study of Poly-4-hydroxybutyrate Mesh (Phasix Mesh) for Hernia Repair in Cohort at Risk for Complication: 60-Month Follow-Up.** *Journal of the Am College of Surgeons* 2022	Phasix™ Mesh	121	60 5	22.0%	NR	2.8%		
Morrison BG, et al. Comparative long-term effectiveness between ventral hernia repairs with biosynthetic and synthetic mesh. *Surg Endosc.* 2023	Phasix™ Mesh	101	Up to 60 5	7.9%	16.8%	6.9% (Superficial) 10.9%(Deep)		
A N Christopher, et al. **An evaluation of clinical and quality of life outcomes after ventral hernia repair with poly-4-hydroxybutyrate mesh.** *Hernia* 2021	Phasix™ Mesh	71	43.1 2	12.7%	NR	7.1%	✓	
Layer T., et al. **Incisional hernia repair with a slowly absorbable P4HB mesh: what happens after the mesh disappears? A retrospective longitudinal clinical study.** *Hernia* 2022	Phasix™ Mesh	**VHWG grade 3: 77** (71.3%) **VHWG grade 4: 31** (28.7%).	41 2	22.2%	NR	24.1%		

These articles are organized by longest to shortest term follow up.

BD

Phasix™ Mesh: *40+ clinical publications and growing*

200K patients impacted

Changing the standard of care since 2013

LEGEND

- 2 for 2 year+ follow up
- 5 for 5 year+ follow up
- ✓ Data reported

QOL- Quality of Life

HEOR- Health, Economics, Outcomes, Research

NR – Not Reported

N/A – Not Applicable

Authors, Article Title, Journal, Year	Product	Patients	Mean Follow-up (Months)	Recurrence	Seroma	Surgical Site Infections	QOL	HEOR
Ventral								
Samuel C. Schecter, et al. **Single-stage abdominal wall reconstruction in contaminated and dirty wound is safe: a single center experience.** *Surgical Endoscopy* 2022	Phasix™ Mesh	34	37 2	6.0% 2	17.6%	12.0%		
J Bueno-Lledó, et al. **Abdominal wall reconstruction with biosynthetic absorbable mesh after infected prosthesis explanation: single stage is better than two-stage approach of chronic mesh infection.** *Hernia* 2021	Phasix™ Mesh	**Phasix™ Mesh:** 30 **Synthetic:** 41	36.5 2	**Phasix™ Mesh:** 6.6% **Synthetic:** 10.7%	**Phasix™ Mesh:** 6.6% **Synthetic:** 10.7%	**Phasix™ Mesh:** 3.3% **Synthetic:** 9.8%		
Adam S Levy, et al. **Poly-4-hydroxybutyrate (Phasix™) mesh onlay in complex abdominal wall repair.** *Surg Endoscopy* 2021	Phasix™ Mesh	105	36 2	17.0%	6.0%	5.0%		
John Scott Roth, et al. **Prospective, multicenter study of P4HB (Phasix™) mesh for hernia repair in cohort at risk for complications: 3-Year follow-up.** *Ann Med Surg* (Lond) 2020	Phasix™ Mesh	121	36 2	17.9%	6.6%	9.3%		
José Bueno-Lledó, et al. **Biosynthetic Resorbable Prosthesis is Useful in Single-Stage Management of Chronic Mesh Infection After Abdominal Wall Hernia Repair.** *World J Surgery* 2021	Phasix™ Mesh	32	34.5 2	3.3%	20.0%	3.3%		
Abdullah Aldohayan, et al. **Laparoscopic Ventral Hernia Repair with Poly-4-Hydroxybutyrate Absorbable Barrier Composite Mesh.** *JSLS* 2021	Phasix™ ST Mesh	26	28 2	0.0%	15.4%	0.0%		
Joseph A Mellia, et al. **Outcomes of Poly-4-hydroxybutyrate Mesh in Ventral Hernia Repair: A Systematic Review and Pooled Analysis.** *Plat Reconstr Surg Global* (Open) 2020	Phasix™ Mesh	453	26.8 2	9.1%	NR	6.8%		
Justin D Faulkner, et al. **Evaluation of Absorbable Mesh for Prophylactic Mesh Augmentation in High-Risk Patients.** *Surg Technol Int* 2021	Phasix™ Mesh	50	26.4 2	8.0% (When Phasix™ Mesh was placed)	4.0%	4.0%		
Deborah Yu, et al. **Comparison of Phasix, polypropylene, and primary closure of the abdominal donor site after bilateral free flap breast reconstruction: Long-term evaluation of abdominal hernia and bulge formation.** *Microsurgery* 2020	Phasix™ Mesh	66	25.2 2	0.0%	**Phasix™ Mesh:** 0% **Polypropylene mesh:** 10% **Primary closure:** 16.7% ($p<0.05$)	NR		
Othman S, et al. **Comparative Effectiveness Analysis of Resorbable Synthetic Onlay and Biologic Intraperitoneal Mesh for Abdominal Wall Reconstruction: A 2-Year Match-Paired Analysis.** *Plast Reconstr Surg* 2022	Phasix™ Mesh	**Phasix™ Mesh:** 44 **Biologics:** 44	24.5 2	**Phasix™ Mesh:** 4.5% **Biologics:** 22.7%	NR	**Phasix™ Mesh:** 18.2% **Biologics:** 25.6%		
Christopher AN, Morris et al. **Resorbable Synthetic Ventral Hernia Repair in Contaminated Fields: Outcomes with Poly-4-Hydroxybutyrate Mesh.** *Plast Reconstr Surg* 2021	Phasix™ Mesh	60	24.2 2	8.3%	NR	16.7%		
Hope WW, et al. **A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial).** *Ann Med Surg* (Lond) 2021	Phasix™ ST Mesh	120	24 2	31.7%	NR	0.0%		
M M J Van Rooijen, et al. **Slowly resorbable biosynthetic mesh: 2-year results in VHWG grade 3 hernia repair.** *Hernia* 2022	Phasix™ Mesh	84	24 2	11.0%	8.3%	13.1%	✓	

These articles are organized by longest to shortest term follow up.

BD

Phasix™ Mesh: *40+ clinical publications and growing*

200K patients impacted

Changing the standard of care since 2013

LEGEND

- 2 for 2 year+ follow up
- 5 for 5 year+ follow up
- ✓ Data reported

QOL- Quality of Life

HEOR- Health, Economics, Outcomes, Research

NR – Not Reported

N/A – Not Applicable

Authors, Article Title, Journal, Year	Product	Patients	Mean Follow-up (Months)	Recurrence	Seroma	Surgical Site Infections	QOL	HEOR
Ventral								
Charles A Messa 4th, et al. **When the Mesh Goes Away: An Analysis of Poly-4-Hydroxybutyrate Mesh for Complex Hernia Repair.** *Plast Reconstr Surg Global* (Open) 2019	Phasix™ Mesh	70	24 2	5.7% 2	8.0%	8.0%	✓	
Margaret A Plymale, et al. **Ventral hernia repair with poly-4-hydroxybutyrate mesh.** *Surg Endosc* 2018	Phasix™ Mesh	31	24 2	0.0%	12.9%	19.0%	✓	
Pakula A, Skinner R. **Outcomes of Open Complex Ventral Hernia Repairs With Retromuscular Placement of Poly-4-Hydroxybutyrate Bioabsorbable Mesh.** *Surg Innov* 2020	Phasix™ Mesh	20	21.1	0.0%	10.0%	10.0%		
Claessen JJM, et al. **Outcomes of mid-term and long-term degradable biosynthetic meshes in single-stage open complex abdominal wall reconstruction.** *Hernia* 2021	Phasix™ Mesh Bio-A®	**Phasix™**: 40 **Bio-A®**: 30	**Median:** 20 **Phasix™**: 35 **Bio-A®**: 11	**Phasix™**:10% **Bio-A®:** 10%	NR	**Phasix™:**25% **Bio-A®:** 23.3%		
Adrienne N Christopher, et al. **Onlay Poly-4-Hydroxybutyrate (P4HB) Mesh for Complex Hernia: Early Clinical and Patient Reported Outcomes.** *J Surg Res* 2021	Phasix™ Mesh	51	20	5.9%	NR	15.7%		
John Scott Roth, et al. **Prospective evaluation of poly-4-hydroxybutyrate mesh in CDC class I/high-risk ventral and incisional hernia repair: 18-month follow-up.** *Surg Endosc* 2018	Phasix™ Mesh	121	18	9.0%	6.0%	9.0%		
Carla Rognoni, et al. **Clinical outcomes and quality of life associated with the use of a biosynthetic mesh for complex ventral hernia repair: analysis of the "Italian Hernia Club" registry.** *Sci Rep* 2020	Phasix™ ST Mesh Phasix™ Mesh	75	18	8.0%	17.0%	4.0%	✓	✓
Blair A Wormer, et al. **Reducing Postoperative Abdominal Bulge Following Deep Inferior Epigastric Perforator Flap Breast Reconstruction with Onlay Monofilament Poly-4-Hydroxybutyrate Biosynthetic Mesh.** *J Reconstr Microsurg* 2017	Phasix™ Mesh	319	16 . 4 ±11.1	NR	**Phasix™ Mesh:** 2.5% **No mesh:** 3.1% (p = 0.75)	**Phasix™ Mesh:** 1.3% **No mesh:** 2.5% (p = 0.45)		
Daniela Kniepeiss, et al. **Prevention of Incisional hernia after liver transplantation (PRINC trial): study protocol for a randomized controlled trial.** *Trials* 2019	Phasix™ Mesh	178	12	NR	NR	NR		
E Vauclair, et al. **What results can be expected one year after complex incisional hernia repair with biosynthetic mesh?** *J Visc Surg* 2021	Phasix™ Mesh	29	12	10.3%	NR	0.0%		
D Charleux-Muller, et al. **Slowly absorbable mesh in contaminated incisional hernia repair: results of a French multicenter study.** *Hernia* 2021	Phasix™ ST Mesh Phasix™ Mesh	**VHWG grade 3:** 170 **VHWG grade 2:** 45	12	12.4%	NR	22.3%		
D Charleux-Muller, et al. **Cost-effectiveness analysis of resorbable biosynthetic mesh in contaminated ventral hernia repair.** *J Visc Surg* 2022	Phasix™ ST Mesh Phasix™ Mesh	94	6	**Phasix™:** 21% **Biologics:** 33%	NR	NR	✓	✓
Diego L Lima, et al. **Versatility of Poly-4-Hydroxybutyrate (Phasix) Mesh in Abdominal Wall Surgery.** *Arq Gastroenterol* 2022	Phasix™ Mesh	51	3.5	4.0%	16.0%	NR		

These articles are organized by longest to shortest term follow up.

BD

Phasix™ Mesh: *40+ clinical publications and growing*

200K patients impacted

Changing the standard of care since 2013

LEGEND

- 2 for 2 year+ follow up
- 5 for 5 year+ follow up
- ✓ Data reported

QOL- Quality of Life

HEOR- Health, Economics, Outcomes, Research

NR – Not Reported

N/A – Not Applicable

Authors, Article Title, Journal, Year	Product	Patients	Mean Follow-up (Months)	Recurrence	Seroma	Surgical Site Infections	QOL	HEOR
Ventral								
Mathilde Mj van Rooijen, et al. **Outcomes of a new slowly resorbable biosynthetic mesh (Phasix™) in potentially contaminated incisional hernias: A prospective, multi-center, single-arm trial.** *Int J Surg* 2020	Phasix™ Mesh	84	3	0.0% 2	8.3%	13.0%		
Laurens Jan van Driel , et al. **Observational Cohort Study on the Use of a Slowly Fully Resorbable Synthetic Mesh (Phasix™) in the Treatment of Complex Abdominal Wall Pathology with Different Grades of Contamination.** *Surg Technol Int* 2021	Phasix™ ST Mesh Phasix™ Mesh	47	2	**Clean:** 5.9% **Clean-Contaminated:** 11.8% **Dirty Cases:** 42.9%	NR	NR		
Salvador Morales-Conde, et al. **Establishing Peer Consensus About the Use of Long-Term Biosynthetic Absorbable Mesh for Hernia (Grades 2–3) as the Standard of Care.** *World Journal of Surgery* 2022	Phasix™ ST Mesh Phasix™ Mesh	255	N/A	N/A	NR	NR		
Joseph F Buell, et al. **Initial Experience With Biologic Polymer Scaffold (Poly-4-hydroxybuturate) in Complex Abdominal Wall Reconstruction.** *Ann Surg* 2017	Phasix™ Mesh	73	NR	**Phasix™ Mesh:** 6.5% **Strattice™:** 23.8% (p = 0.049)	Time to drain removal: **Phasix™ Mesh:** 10 days **Strattice™:** 14 days (p = 0.002)	**Phasix™ Mesh** 12.9% **Strattice™** 31.0% (p = 0.073)		✓

These articles are organized by longest to shortest term follow up.

Revision Date: May 24, 2023

BD, Warwick, RI, 02886, U.S.
1.844.8.BD.LIFE (844.823.5433)

bd.com